19 results
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
7 Aug 24
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
4:06pm
, 2024, compared to $45.6 million for the same period in 2023.
GAAP and Non-GAAP Operating Expenses
Research and development (R&D) expenses were $40.3 … million for the second quarter ended June 30, 2024, compared to $47.5 million for the same period in 2023. The decrease in second quarter 2024 R&D expenses
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
6 May 24
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
8:03am
to $44.8 million for the same period in 2023.
GAAP and Non-GAAP Operating Expenses
Research and development (R&D) expenses were $43.2 million … for the first quarter ended March 31, 2024, compared to $44.6 million for the same period in 2023. The decrease in first quarter 2024 R&D expenses of $1.5
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
28 Feb 24
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
4:07pm
drove the decrease in revenue.
GAAP and Non-GAAP Operating Expenses
Research and development (R&D) expenses were $47.0 million and $182.9 million … . The increase in fourth quarter 2023 R&D expenses of $9.0 million was primarily driven by non-cash expenses related to the change in the estimated fair
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
7 Nov 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
4:08pm
and development (R&D) expenses were $43.8 million for the third quarter ended September 30, 2023, compared to $41.6 million for the same period in 2022 … . The increase in third quarter 2023 R&D expenses was primarily driven by personnel-related expenses, mainly due to an increase in headcount to expand our
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
8 Aug 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
4:10pm
in December 2022, which drove the $35.7 million decrease in revenue.
GAAP and Non-GAAP Operating Expenses
Research and development (R&D) expenses were $47.5 … million for the second quarter ended June 30, 2023, compared to $43.7 million for the same period in 2022. The increase in second quarter 2023 R&D expenses
8-K
EX-99.1
t2hxwsledg5 z6g
4 May 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
4:11pm
8-K
EX-99.1
qlafj7 f6x2
8 Nov 22
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
4:07pm
8-K
EX-99.1
vsugaqn6lq4qbh p9bng
4 Aug 22
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights
4:16pm
8-K
EX-99.1
qbyw13t z6fmbqe
10 May 22
Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights
4:14pm
8-K
EX-99.1
6444ws
29 Mar 22
Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
4:15pm
8-K
EX-99.1
avn1zf
12 Nov 21
Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business Highlights
8:20am
8-K
EX-99.1
gzr 582h2lfq
12 Aug 21
Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights
4:18pm
424B4
1ljvbxu3tt0iculx6q
18 Jun 21
Prospectus supplement with pricing info
12:00am
S-1/A
cgl2iiti9t86z68vyh
9 Jun 21
IPO registration (amended)
7:12am
S-1
2ff24bnfr lkks8k2a6i
25 May 21
IPO registration
5:28pm
S-1
EX-10.21
pcdeon
25 May 21
IPO registration
5:28pm
DRS/A
qnu8a14hwse 3j
12 May 21
Draft registration statement (amended)
12:00am
DRS
EX-10.21
yvg1nkb7nj b5
12 Apr 21
Draft registration statement
12:00am
DRS
sm7f9wye3rl9nlckq
12 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next